The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize procedures to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.
grades of recoMMendation and levels of evidence • A: Experimental or observational studies of higher consistency.
• B: Experimental or observational studies of lower consistency.
• C: Cases reports (non-controlled studies).
• D: Opinion without critical evaluation, based on consensus, physiological studies or animal models.
oBJective
The objective of this guideline is to present the main available evidence comparing transurethral resection of the prostate with laser prostatectomy (PVP) in patients with benign prostatic hyperplasia (BPH) in relation to the main peri-or postoperative outcomes, allowing the formalization of recommendations directly supported by such evidence.
description of evidence collection Method
This guideline followed the standard of a systematic review with evidence retrieval based on the EBM (evidence-based medicine), so that clinical experience is integrated with the ability to critically analyze and apply scientific information rationally, thus improving the quality of medical care. EBM uses existing and currently available scientific evidence, with good internal and external validity for the application of its results in clinical practice.
1,2
Systematic reviews are currently considered the level I of evidence for any clinical question by systematically summarizing information on a particular topic through primary studies (clinical trials, cohort studies, case-control or cross-sectional studies) using a reproducible methodology, in addition to integrating information on effectiveness, efficiency, efficacy and safety. 1, 2 We use the structured mode of formulating the question synthesized by the acronym PICO, where P stands for patient or population presenting prostatic hyperplasia, I stands for intervention with laser prostatectomy (PVP), C stands for comparison with transurethral resection of the prostate and O stands for the outcome of efficacy and harm. Based on the structured question, we identified the descriptors that formed the basis of the search for evidence in the following databases: Medline, Embase, Central Cochrane, Cochrane Library. Thus, 367 studies were retrieved, and, after applying the eligibility criteria (inclusion and exclusion), 11 were selected to answer the clinical question (Annex I).
clinical question
What is the effectiveness of laser prostatectomy (PVP) in patients with benign prostatic hyperplasia? introduction Benign prostatic hyperplasia (BPH) is a common disease with high morbidity in the elderly. Patients with urinary symptoms, mainly obstructive, may require surgical treatment, which is usually performed through transurethral resection of the prostate (conventional TURP). Complications of the procedure include bleeding, TURP syndrome (water intoxication), urinary incontinence, urinary retention and sexual dysfunction, especially regarding ejaculation function.
In an attempt to reduce morbidity, the development of new alternative surgical procedures has been encouraged, including photoselective vaporization of the prostate (PVP) using laser.
The laser emits light at a wavelength of 532 nm, which will be absorbed by hemoglobin, leading to heating of the prostatic tissue. In the beginning, PVP was performed with potassium-titanyl-phosphate (KTP) laser at 60 W and later at 80 W. Then, laser prostatectomy (PVP) using a high-performance system (HPS) 120 W laser or XPS 180 W laser was introduced, aiming at reducing the limitations of KTP, as well as improving results compared with conventional TURP.
The goal is to reduce hospitalization time, bleeding, and other complications, but there is some doubt as to the effectiveness of laser treatment with regard to the replacement of conventional TURP as a first-line treatment.
selected evidence results
Patients (> 50 years) with urinary flow (UF) ≤ 15 mL/s; prostate symptoms score (IPSS) ≥ 12; prostatic volume (PV): 15-85 cm 3 (USG); obstruction (AG nomogram) (N: 76), were treated with PVP using KTP 80 W laser and star pulse quasicontinuous wave laser (laserscope) emitting green light at a wavelength of 532 nm (N: 38) compared with transurethral resection of the prostate (conventional TURP) (N: 38), with the following outcomes being assessed: urinary flow, international prostate symptoms score (IPSS), quality of life score (QoL), bother score, postvoid residual volume (PVRV), surgical time, PO Hb, length of catheterization and length of hospitalization after 6 weeks and at 3, 6 and 12-month follow-up. The use of laser leads to significant increase in UF (mL/s), decline in IPSS, increase in quality of life (QoL), increase in bother score, increase in postvoid residual volume (PVRV) (mL), shorter bladder irrigation time (min) and shorter length of hospitalization (days), and less decrease in hemoglobin levels (g/dL). There is no difference in surgical time (min).
3 (B) In patients aged 68 years, BPH; PV: 70 to 100 mL; UF < 15 mL/s; PVRV > 150 mL; IPSS > 7 (N: 76), PVP with KTP/532 high-power laser emitting green light (80W) (N: 39) was compared with transurethral resection of the prostate (conventional TURP) (N: 37), and the following outcomes were assessed: IPSS and IIEF-5 scores; PV; PVRV; UF; urinary retention; transfusion; re-intervention after 6 months. There was a significant benefit with the use of PVP laser in relation to all analyzed outcomes; however, there was an increased risk of urinary retention (NNH: 8) and reintervention (NNH: 6).
(B)
Patients with BPH; IPSS > 16; UF < 15 mL/s; PV < 100 mL; PVRV < 100 mL (N: 120) treated with HPS 120-W laser using lithium triborate (LBO) crystal, producing 532-nm waves (N: 60) or transurethral resection of the prostate (conventional TURP) (N: 60) were assessed regarding surgical time; Hb; transfusion; length of catheterization; length of hospitalization; complications; IPSS; PVRV; PV; UF at 1, 3, 6, 12, 24 and 36 months. The use of laser compared with conventional TURP significantly increased the outcome of surgical time, but reduced the outcomes of bleeding, length of catheterization and length of hospitalization. There is a decline in the risk of transfusions (NNT: 6) and intraoperative complications (NNT: 5), but also an increase in the number of early (NNH: 2) and late (NNH: 8) complications.
5 (B) PVP treatment using HPS 120-W laser in 50 patients was compared with transurethral resection of the prostate (conventional TURP) in other 50 patients, the following inclusion criteria being adopted: BPH; IPSS > 15; PV < 80 cm 3 ; urinary flow < 15 mL/s. At 1, 3, 6, 12 and 24 months, the following outcomes were assessed: IPSS; urinary flow; surgical time; Hb; transfusion; complications; length of hospitalization; length of catheterization. The results of laser intervention reduced blood loss, length of catheterization and length of hospitalization compared with conventional TURP. Nevertheless, they increased surgical time. Regarding catheterization with a probe < 20 Fr, intraoperative and late complications, there is a benefit to using laser with NNT = 1, 10 and 6, respectively. 6 (B) In patients with BPH; > 50 years; IPSS ≥ 12 and bother score ≥ 3; Qmax < 12 mL/s; prostatic volume between 25 mL and 80 mL; PVRV < 300 mL (N: 139), two treatment modalities were compared: PVP HPS 120-W laser (N: 69) and transurethral resection of the prostate (conventional TURP) (N: 70) based on IPSS; length of hospitalization; Qmax; PVRV; complications; sexual symptoms; quality of life at 12 months. Only surgical time was shorter using laser treatment, while none of the other outcomes presented significant differences, although length of hospitalization was shorter with conventional TURP. 7 (B) Bleeding (measured by Hb) and length of catheterization were less noticeable in 64 patients with BPH (age > 50 years; IPSS > 7; prostatic volume > 20 and < 80 cc; urinary flow (Q max) < 15 mL/s) treated with PVP (laser emitting green light at a wavelength of 532 nm, 30 to 80W) compared with 64 patients treated with conventional TURP, at 12-month follow-up. Nevertheless, surgical time was longer in the group treated with PVP. 8 (B) In patients with lower urinary tract symptoms due to BPH (N: 20) treated with PVP HPS 120-W laser) or transurethral resection of the prostate (conventional TURP), there is no difference between the two treatment modalities regarding outcomes expressed by IPSS, IIEF-5 and ICIQ-SF scores, or the following measures: PVRV and Qmax, at 12-month follow-up. 9 (B) In patients with BPH, IPSS > 15, treatment failure, Qmax < 15 mL/s and prostatic volume < 100 mL (N: 200), comparison between PVP (HPS with 80-W KTP laser) (N: 100) and transurethral resection of the prostate (conventional TURP) (N: 100) made it possible to assess the outcomes of length of catheterization, length of hospitalization, periand postoperative complications, IPSS and QoL, Qmax, PVRV and prostatic volume, at 1, 3, 6, 12, 24 and 36-month follow-up. The outcomes measured at 24 months did not present significant difference between the two treatment modalities in relation to the scores: quality of life (QoL), IPSS, urinary flow, PVRV and PO Hb. But there was significant benefit in favor of the laser in the following outcomes: prostatic volume, length of catheterization and length of hospitalization. Conventional TURP yielded a shorter surgical time. Regarding complications, there was a decline in the rate of transfusion and perforation of the prostatic capsule with the use of the laser.
10 (B) Patients with BPH and moderate or severe lower urinary tract symptoms (IPSS >16), therapeutic failure, maximum flow rate (Qmax) < 15 mL/s, PVRV > 100 mL and prostatic volume < 100 mL (N: 62) were treated comparatively with PVP (HPS 180-W laser) (N: 31) and transurethral resection of the prostate (conventional TURP) (N: 31). At the 12-month follow-up, surgical time was longer using laser, but the lengths of hospitalization and catheterization were shorter, with lower rates of transfusion (NNT: 5) and perforation (NNT: 6). The other outcomes did not differ: hemoglobin and transfusion, other peri-and postoperative complications, IPSS, QoL, Qmax, PVRV and prostatic volume.
11 (B) Except for a shorter length of hospitalization, the treatment of patients with symptoms of BPH obstruction; 64 years; IPSS > 7; Qmax < 15 mL/s; prostatic volume < 80 mL; PVRV > 150 mL (N: 124) with PVP 120-W laser (N: 60), compared with transurethral resection of the prostate (conventional TURP) (N: 64), failed to demonstrate superiority or inferiority when analyzed in relation to the following outcomes: IPSS; length of hospitalization; Qmax; PVRV; complications; sexual symptoms; re-intervention or transfusion at 24 months. 12 (B) In patients with lower urinary tract symptoms due to BPH with obstruction; aged 40 to 80 years; IPSS ≥ 12; Qmax < 15 mL/s; prostatic volume ≤ 100 mL (N: 281), there was no difference between treatment with transurethral resection of the prostate (conventional TURP) (N: 142) and PVP with 180-W XPS laser vaporization (N: 139), at 24 months, regarding the following outcomes: quality of life (QoL); IPSS; urinary flow (mL/s); PVRV; prostatic volume; re-treatment and complications.
13 (B) evidence suMMary
There is evidence, with high risk of bias, of the benefit of laser prostatectomy (PVP) in patients with BPH compared to conventional TURP regarding UF, IPSS, QoL, bother score, IIEF-5 score, postvoid residual volume (PVRV), bladder irrigation/length of catheterization, length of hospitalization (days), Hb decline, prostatic volume, urinary retention, transfusion (NNT: 6), re-intervention (?), intraoperative complications (NNT: 5), early (NNT: 10) and late (NNT: 6) complications at different times, from 6 to 24 months. There is evidence, with the same high risk of bias, of lower PVP benefit compared to conventional TURP regarding risk of urinary retention (NNH: 8), re-intervention (NNH: 6), surgical time, number of early (NNH: 2) and late (NNH: 8) complications, as well as length of hospitalization.
There is no difference between the two treatment modalities in relation to the outcomes expressed by the scores: IPSS, IIEF-5 and ICIQ-SF, or the following measurements: urinary flow, PVRV, prostatic volume and Qmax, length of hospitalization, complications, sexual symptoms, re-intervention, need for transfusion or re-treatment at 12 to 24 months of follow-up. 
Articles retrieved
The obtaining of evidence to be used to analyze the clinical question followed the steps of: elaboration of the clinical question, structuring of the question, search for evidence, critical evaluation and selection of evidence, presentation of results and recommendations.
The bases of scientific information consulted were: Medline via Pubmed, Embase, Central Cochrane and Cochrane Library.
A total of 367 articles were retrieved, of which 22 were selected after reading the title and abstract; of these 11 had the full text accessed to answer the proposed clinical question (Table 1) .
3-13
Inclusion and exclusion criteria Phase III randomized controlled clinical trials, systematic reviews (with or without meta-analyzes), comparative (or non-comparative) studies were included, and, in their absence, the best evidence available to answer the clinical question within the limits of PICO.
According to study design Narrative reviews, case reports, case series, studies presenting preliminary results only were, in principle, excluded from the selection. Systematic reviews and meta-analyzes were used with the principle of retrieving references that may have been lost since the initial search strategy. Controlled clinical trials were assessed based on the Jadad 14 and GRADE 15 scores.
Language
We included studies available in Portuguese, English or Spanish.
According to type of publication
Only full-text studies were considered for critical assessment. 
Study data
References, study design, Jadad, strength of evidence Sample calculation Estimated differences, power, level of significance, total of patients
Patient selection
Inclusion and exclusion criteria
Patients
Recruited, randomized, prognostic differences
Randomization

Description and blinded allocation
Patient follow-up
Time, losses, migration
Treatment protocol
Intervention, control and blinding
Analysis
Intention to treat, analyzed, intervention and control
Outcomes considered
Primary, secondary, outcome measurement instrument
Result
Benefit or harm in absolute data, mean benefit or mean harm 
Exposure of results
For results with available evidence, the population, intervention, outcomes, presence or absence of benefit and/ or harm, and controversies will be defined in a specific manner, whenever possible (Table 5) . The results will be preferably expressed in absolute data, absolute risk, number needed to treat (NNT), or number needed to harm (NNH), and occasionally using mean and standard deviation (Tables 6-16 ).
Recommendation
The recommendations will be elaborated by the authors of the review, with the initial characteristic of synthesis of the evidence, and later validated by all the authors who participate in the elaboration of this guideline.
The grade of recommendation stems directly from the available strength of included studies, according to the Oxford scale 17 and the GRADE system. 
